PRP vs BMAC Comparison: What Patients Should Understand Before a Consultation

The short answer

In a PRP vs BMAC comparison, the honest short answer is that these are two different orthobiologic preparations rather than two versions of the same product. Platelet-rich plasma (PRP) is made from a sample of your own blood that is processed to concentrate platelets and the growth factors they release. Bone marrow aspirate concentrate (BMAC) is made from a sample of your own bone marrow, typically drawn from the hip area, that is processed to concentrate marrow cells and other components. Both are autologous, meaning the material comes from your own body, and both have been studied as non-surgical options for certain musculoskeletal conditions.^[PubMed]

The clearest head-to-head evidence so far comes from knee osteoarthritis. In one randomized trial, 90 participants aged 18 to 80 with symptomatic knee osteoarthritis (Kellgren-Lawrence grades 1-3) received a single intra-articular injection of either leukocyte-rich PRP or bone marrow concentrate. Both groups improved significantly from baseline by one month, and those improvements were sustained for 12 months, with no statistically significant difference between the two groups at any time point. The authors concluded that neither treatment provided a superior clinical benefit in that population.^[PubMed]

That result does not mean the two are interchangeable for every patient or every condition. It reflects one trial, in one joint, using one preparation of each product. The same paper notes that PRP has stronger clinical evidence behind it while bone marrow concentrate has more limited support, and that the trial had no control group, so patients knew which treatment they received. A separate placebo-controlled trial of BMAC in knee osteoarthritis illustrates why caution is warranted: pain scores fell in both the BMAC-treated and saline-treated knees, and the difference between them was not statistically significant.^{[PubMed][PubMed]}

So the useful answer to "which is better" is: for mild to moderate knee osteoarthritis, the best available direct comparison found them roughly equivalent over 12 months, while the broader evidence base is uneven and still developing. What this comparison can do is explain how the preparations differ, what the research can and cannot establish, and which questions to bring to a consultation so the discussion is grounded in your actual diagnosis rather than a general claim.^[PubMed]

What the knee osteoarthritis trials actually showed

Two randomized trials are worth understanding in detail, because they are frequently summarized loosely. The first compared bone marrow concentrate with PRP directly. It enrolled 90 participants with symptomatic knee osteoarthritis graded Kellgren-Lawrence 1 to 3, randomized them to a single injection of leukocyte-rich PRP or bone marrow concentrate, and measured the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the subjective International Knee Documentation Committee (IKDC) questionnaire before injection and at 1, 3, 6, 9, and 12 months afterward. Baseline scores did not differ significantly between groups. All scores in both groups improved significantly by one month (P < .001) and stayed improved through 12 months, with no difference between PRP and bone marrow concentrate at any time point. The authors had hypothesized that bone marrow concentrate would be more effective; it was not.^[PubMed]

The second trial tested BMAC against a placebo. Twenty-five patients with bilateral knee pain from bilateral osteoarthritis received BMAC in one knee and a saline injection in the other, so each person served as their own control. Fifty-two milliliters of bone marrow was aspirated from the iliac crests and concentrated in an automated centrifuge, then combined with platelet-poor plasma for injection. There were no serious adverse events from the BMAC procedure. Pain and function scores in both knees decreased significantly from baseline at 1 week, 3 months, and 6 months (P ≤ .019 for all), but the pain relief did not differ significantly between the BMAC-treated and saline-treated knees (P > .09 for all). The authors concluded that further study is needed to determine mechanisms of action, duration of efficacy, optimal treatment frequency, and regenerative potential.^[PubMed]

Read together, these trials support a narrow, useful conclusion: in knee osteoarthritis, PRP and BMAC have each been associated with improved patient-reported pain and function, but neither has been shown to be superior to the other, and at least one BMAC trial could not separate the treatment from a saline injection. They do not establish that either product regrows cartilage, and they do not establish that any particular clinic's preparation will behave the same way.^{[PubMed][PubMed]}

How the two preparations differ

Beyond the trial results, patients usually want to understand the practical differences in source material and collection. Blood collection for PRP is generally simpler than a bone marrow aspiration, which is a more involved procedure. The two preparations also differ in what is concentrated, and preparation methods and cell or platelet yields are not standardized across systems or clinics, so results reported for one formulation do not automatically transfer to another.^{[PubMed][PubMed]}

Questions worth asking before you decide

A comparison only becomes useful when it is applied to your situation. These questions are designed to move the conversation from general claims about orthobiologics to the specifics of your diagnosis and the evidence behind any recommendation.

Limits and responsible use

This article is general education, not medical advice, and it cannot tell you whether PRP or BMAC is right for you. Orthobiologic treatments are not appropriate for every musculoskeletal problem, and outcomes are not guaranteed for any patient. The cited trials have specific limitations: the head-to-head comparison had no control group, so participants knew which treatment they received; the placebo-controlled BMAC trial was small, with 25 patients; and each trial tested a single preparation of each product, so the findings may not generalize to other formulations or processing methods.^{[PubMed][PubMed]}

The evidence base is still developing, and direct comparisons between PRP and BMAC remain limited to a small number of conditions. A qualified clinician who has examined you and reviewed your imaging and history is the right person to discuss risks, benefits, alternatives, and whether either option fits your care plan.

Next steps

For current appointment, location, or contact information, visit the official website.

Frequently Asked Questions

Is BMAC better than PRP for knee osteoarthritis?

In the best available direct comparison, no. A randomized trial of 90 participants with mild to moderate knee osteoarthritis found that both leukocyte-rich PRP and bone marrow concentrate improved pain and function scores significantly by one month, that improvements were sustained for 12 months, and that there was no statistically significant difference between the two groups at any time point. The authors concluded neither treatment provided superior clinical benefit in that population. This reflects one trial in one joint using one preparation of each product.

Did the BMAC trial show that BMAC works better than a placebo?

No. In a small placebo-controlled trial, 25 patients with bilateral knee osteoarthritis received BMAC in one knee and saline in the other. Pain and function scores improved significantly in both knees at 1 week, 3 months, and 6 months, but the pain relief did not differ significantly between the BMAC-treated and saline-treated knees. The authors called for further study of mechanisms, duration of efficacy, optimal treatment frequency, and regenerative potential.

Do these trials prove that PRP or BMAC regrows cartilage?

No. The cited trials measured patient-reported pain and function outcomes, not cartilage regrowth. The head-to-head trial used the WOMAC and IKDC questionnaires, and the placebo-controlled trial used OARSI and visual analog scale measures. Claims that either treatment regrows cartilage are not supported by these studies.

Why do the trial limitations matter to me?

The head-to-head comparison had no control group, so participants knew which treatment they received, and the placebo-controlled BMAC trial was small with 25 patients. Each trial also tested a single preparation of each product, and preparation methods are not standardized across clinics. That means results from these studies may not apply to a different formulation or to your specific condition.

What should I ask a clinician before choosing between PRP and BMAC?

Ask what your specific diagnosis is and which tissue is involved, how the clinic prepares the product and whether the method is standardized, what evidence exists for your particular condition, how the option compares with alternatives such as physical therapy or corticosteroid injections, and what recovery and follow-up usually look like.